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ABSTRACT
JMJD3 (Jumonji domain containing-3), a histone H3 Lys27 (H3K27) demethylase, 
has been reported to be involved in the antigen-driven differentiation of germinal 
center B-cells. However, insight into the mechanism of JMJD3 in DLBCL (Diffuse 
large B-cell lymphoma) progression remains poorly understood. In this study, we 
investigated the subtype-specific JMJD3-dependent survival effects in DLBCL. Our 
data showed that in the ABC subtype, silencing-down of JMJD3 inhibited interferon 
regulatory factor 4 (IRF4) expression in a demethylase activity-dependent fashion. 
IRF4 reciprocally stimulated expression of JMJD3, forming a positive feedback loop 
that promoted survival in these cells. Accordingly, IRF4 expression was sufficient 
to rescue the pro-apoptotic effect of JMJD3 suppression in the ABC, but not in the 
GCB subtype. In contrast, ectopic overexpression of BCL-2 completely offset JMJD3-
mediated survival in the GCB DLBCL cells. In vivo, treatment with siRNA to JMJD3 
reduced tumor volume concordant with increased apoptosis in either subtype. This 
suggests it is a common target, though the distinctive signaling axes regulating DCBCL 
survival offer different strategic options for treating DLBCL subtypes. 
INTRODUCTION
Transcriptional repression and activation of critical 
genes, as regulated by post-translational modification of 
histone tails, plays an essential role in the developmental 
process or cellular differentiation. This includes neural 
differentiation, the lineage commitment of embryonic 
stem cells, and terminal differentiation of progenitor 
cells. One important repressive modification, histone 
methylation on specific lysine residues, is manipulated 
by different families of histone lysine methyltransferases 
and demethylases, including Polycomb group (PcG) of 
proteins, LSD1 and JmjC-domain-containing proteins [1]. 
The mutation or dysregulation of these proteins have been 
reported to be related to cancer and other diseases [2–5].
JMJD3 and UTX are demethylases that remove 
the tri-methyl mark from H3K27. They activate the 
transcriptional expression of genes by demethylating 
H3K27me3 and disassociating polycomb group proteins. 
JMJD3 expression is influenced by both specific gene 
expression and cellular context. This contributes to both 
differentiation [6–11] and tumor suppression [12–14], 
as well as tumor cell survival [15, 16]. It is notable 
that JMJD3 plays a role in the B-cell differentiation. 
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Moreover, JMJD3 is aberrantly overexpressed and seems 
to contribute to pathogenesis of Epstein-Barr virus-
associated Hodgkin’s lymphoma [17–19].  
Diffuse large B-cell lymphoma (DLBCL) is the 
most common type of Non-Hodgkin lymphoma. It is an 
aggressive and heterogeneous disease comprising two 
major distinct subtypes (ABC and GCB subtypes) that 
responds differently to standard treatments. Various genetic 
lesions, including mutations in PRDM1, CARD11, CD79B, 
TNFAIP3, MYD88 and translocations of MYC, BCL-2 and 
BCL6, have been shown to promote the tumorigenesis and 
the survival of DLBCL [20–28]. Furthermore, the majority 
of lesions targeting histone or chromatin modification are 
also a prominent feature of the DLBCL [19, 29–31]. In 
this study, we showed that aberrantly upregulated JMJD3 
exerts an anti-apoptotic effect in DLBCL and acted as a 
potent positive regulator of DLBCL survival. Moreover, 
we characterized distinct mechanisms by which JMJD3 
regulates survival in different subtypes of DLBCL.
RESULTS
JMJD3 is over-expressed in tumor tissues of 
DLBCL and cultured DLBCL cell lines
To investigate the expression level of JMJD3 
in DLBCL, we first performed immunohistochemical 
analysis of JMJD3 on the tissue microarray composed 
of 100 surgical DLBCL samples. The intensity of 
immunostaining was scored using a scale from 0 to 3, 
and categorized the samples into three main groups, low 
(0 –  1), moderate (2) or high (3). Hierarchical clustering 
was performed on the data segregating the tumors into 
three groups based on the intensity of JMJD3 staining. 
Relative to normal lymph node controls, expression was 
strong in 92% of the DLBCL samples. Similarly, high 
levels of expression were also observed in Hodgkin’s 
lymphoma, mucosa-associated B cell lymphoma and T cell 
lymphoma samples (data not shown) (Figure 1A). This 
suggested a general tumor-facilitating role for JMJD3. 
In vitro, although highly heterogeneous, JMJD3 expression 
was generally elevated in most DLBCL cell lines when 
compared with normal B cell line (HMy2.CIR) at both the 
mRNA and protein levels (Figure 1B and 1C). 
Depletion of JMJD3 induces apoptosis in 
DLBCL cells 
To investigate the role of JMJD3 in the pathogenesis 
of DLBCL, we first assessed the effect of JMJD3 on the 
survival in the cultured cell line models of DLBCL. 
Ectopic over-expression of JMJD3 increased cellular 
viability in the control B cells and DLBCL cells, while 
suppression of JMJD3 decreased the viability of DLBCL 
cells (Figure 2A and 2B). Then, FACS analysis of 
annexin-V/propidium iodide (PI) stained samples were 
performed to evaluate the apoptotic level. Our data 
revealed that suppression of JMJD3 induced apoptosis in 
the DLBCL cells (Figure 2C). Consistent with a role for 
JMJD3 in preventing apoptosis, suppression of JMJD3 
stimulated maturation of caspase-3 (Figure 2D). Taken 
together, these results suggest that JMJD3 plays an critical 
role in the regulation of apoptosis in DLBCL cells.
IRF4 is a target gene regulated by JMJD3
Interferon regulatory factor (IRF) family plays 
central roles in the cellular differentiation of hematopoietic 
cells [32]. Moreover, several IRF family members exert 
important effects on the regulation of both cell cycle and 
apoptosis in DLBCL [33, 34]. Next, we characterized 
the effect of JMJD3 depletion on the regulation of 9 IRF 
family genes in DLBCL cells. Real-time PCR analysis 
revealed that depletion of JMJD3 by specific siRNA 
remarkably suppressed the expression of IRF4 and IRF5 
in both ABC (OCI-Ly3) and GCB (OCI-Ly19) DLBCL 
cells (Figure 3A and 3B). Since IRF4 expression acts as 
a hallmark to dividing ABC and GCB DLBCL [35], we 
therefore subjected IRF4 expression to further analysis. 
Chromatin immunoprecipitation (ChIP) assays were 
used to identify whether JMJD3 expression influenced 
H3K27 trimethylation in the IRF4 promoter region. 
As previously shown [11], a sharp increase in H3K27 
trimethylation was observed at the IRF4 promoter after 
JMJD3 suppression (Figure 3C and 3D). Collectively, 
these results suggest that silencing-down of JMJD3 
inhibits the expression of IRF4 via increase H3K27 
trimethylation at the IRF4 promoter.
NF-κB signaling mediates the JMJD3-IRF4 axis 
induced survival in ABC DLBCL cells
To establish whether IRF4 is the downstream 
gene which mediates the apoptotic program triggered 
following JMJD3 depletion in DLBCL cells, we depleted 
IRF4 in both ABC (OCI-ly3 and SU-DHL-2) and GCB 
(OCI-ly19 and VAL) DLBCL cells. The depletion of 
IRF4 was sufficient to induce apoptosis in ABC, but not 
GCB subtypes of DLBCL (Figure 4A). Supporting these 
results, down-regulation of IRF4 only selectively induced 
the maturation of procaspase 3 in ABC cells (Figure 4B). 
Complementing these results, increased IRF4 expression 
only rescues JMJD3 depletion mediated apoptosis in the 
ABC subtype cells (Figure 4C and 4D). This data suggests 
that JMJD3 might exert anti-apoptotic effect via distinct 
regulatory mechanism in these two subtypes of DLBCL.
NF-κB pathway is constitutively activated in ABC 
subtype of DLBCL and IRF4 regulates the NF-κB gene 
expression signature [34]. Then, we determined the 
role of IRF4 in the pathogenesis of DLBCL. We tested 
whether IRF4 rescued the JMJD3 depletion induced 
apoptosis via suppressing NF-κB signaling. Inhibitor of 
NF-κB signaling selectively induced apoptosis in ABC 
cells (Figure 4E). We assessed the phosphorylation of 
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Figure 1: The expression of JMJD3 in DLBCL patients and cell lines is heterogeneous. (A) The distribution of JMJD3 
heterogeneous expression in DLBCL tissues samples from 100 patients (left), Immunohistochemistry showing the variant expression of 
JMJD3 in DLBCL tissues and normal lymph node (right). Scale bar, 50 μm. (B) RNA (shown by real time PCR) levels of JMJD3 in normal 
B cell line and DLBCL cell lines. GAPDH has been used as a loading control. (C) JMJD3 protein was resolved by immunoblotting and 
levels in the normal B cell and DLBCL cell lines were quantified via densitometry.
Figure 2: Downregulation of JMJD3 promotes apoptosis in DLBCL cell. The viability of ABC and GCB DLBCL cells 
ectopically expressing JMJD3 (A) or with siRNA-suppressed JMJD3 expression (B) was evaluated after 3 days. (C) Representative 
apoptosis analysis using annexin-V/PI staining and flow cytometry of DLBCL cells treated with scrabble control siRNA or JMJD3 siRNA 
for 48 h. (D) Immunoblot assay showing the depletion of JMJD3 proteins in DLBCL cells as compared with the scrabble control siRNA and 
the effect of JMJD3 depletion on cleaved caspase3 and pro-caspase3 expression in DLBCL cells. The data shown are the mean ± S.E.M. of 
at least three independent experiments (*P < 0.05, **P < 0.01, Student’s t-test).
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IκBα, in the cytosol. In tandem, we also evaluated the 
nuclear translocation of NF-κB. As would be expected 
in this model, depletion of JMJD3 reduced IKK activity 
and the nuclear translocation of NF-κB in ABC DLBCL 
cells. Ectopic over-expression of IRF4 in JMJD3-depleted 
ABC cells was sufficient to rescue the inhibited NF-κB 
signaling (Figure 4F), suggesting that IRF4 mediates the 
anti-apoptotic effect of JMJD3 via NF-κB signal pathway 
in ABC cells. Interestingly, ectopic over-expression of 
IRF4 also up-regulated the expression of JMJD3 in an 
NFkB dependent manner (Figure 4G and 4H). Therefore, 
it suggested a positive feedback mechanism perpetuated 
this pro-survival pathway in ABC cells.  
BCL-2 mediates the survival effect of JMJD3 in 
GCB DLBCL cells
The effect that IRF4 rescued the apoptosis induced 
by JMJD3 depletion could only be observed in the 
ABC DLBCL cells, implicating alternative mechanism 
which mediates the JMJD3 related survival in the GCB 
DLBCL cells. In hormone-dependent breast cancer, the 
transcriptional activation of the survival gene BCL2 is 
dependent on the simultaneous inactivation of H3K27 
methyltransferase and subsequent demethylation of H3K27 
at a poised enhancer by ERα-dependent recruitment of 
JMJD3 [16]. Therefore, we evaluated whether BCL2 is 
Figure 3: IRF4 is a downstream gene regulated by JMJD3. (A) Expression levels of genes of interferon regulatory factor family 
(IRF1, IRF2, IRF3, IRF4, IRF5, IRF6, IRF7, IRF8, and IRF9) in OCI-Ly3 (ABC DLBCL, left panel) and OCI-Ly19 (GCB DLBCL, right 
panel) cells depleted or not of JMJD3 via JMJD3 siRNA or scrambled control siRNA. The mRNA expression levels were determined by 
real time PCR and normalized against the expression levels of GAPDH. (B) Immunoblot assay evaluating JMJD3 depletion and IRF4 
expression in OCI-Ly3 and OCI-Ly19 cells.  (C) Schematic diagram of IRF4 promoter regions (upper panel). ChIP-PCR analysis of 
H3K27me3 mark of the IRF4 promoter in OCI-Ly3 cells depleted JMJD3 or not. Mouse IgG was used as a negative control, with input 
used as loading control (lower panel). (D) Quantification of the ChIP-PCR analysis results (quantification of densitometric measurement of 
signal intensity shown). The data shown are the mean ± S.E.M. of three independent experiments (*P < 0.01, Student’s t-test).
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a target gene of JMJD3 in GCB DLBCL cells. As shown 
(Figure 5A and 5B), a significant decrease in Bcl- 2 
protein was observed upon depletion of JMJD3 in the 
GCB DLBCL cells. ChIP assays revealed an increase in 
H3K27 trimethylation at the BCL2 promoter following 
depletion of JMJD3 in OCI-Ly19 cells (Figure 5C 
and 5D). Collectively, these results suggested that JMJD3 
promoted the expression of Bcl-2 via suppressing the 
H3K27 trimethylation of BCL2 promoter in GCB DLBCL 
cells. Accordingly, ectopic over-expression of BCL2 
was sufficient to attenuate apoptosis induced by JMJD3 
depletion in the GCB DLBCL cells (Figure 5E and 5F). 
This data suggested that Bcl-2 mediates the cell-survival 
effect of JMJD3 among GCB DLBCL cells.
Bcl-2 mediates a limited survival effect of 
JMJD3 in ABC DLBCL cells
Considering that Bcl-2 acts as a broad and potent 
cell survival effector, which is also expressed in the ABC 
subtype; therefore, we examined whether Bcl-2 expression 
was involved in the survival of the ABC DLBCL cells. 
Data showed that expression of Bcl-2 was decreased upon 
depletion of JMJD3 in the ABC DLBCL cells. ChIP assays 
revealed an increase in H3K27 trimethylation at the BCL2 
promoter following depletion of JMJD3 in OCI-Ly3 cells 
(Figure 6A–6D). These results suggested BCL2 gene as 
target of JMJD3 in the ABC DLBCL cells. Notably, IRF4 
stimulated the expression of Bcl- 2 and administration of 
NF-kB inhibitor blocked the IRF-induced Bcl-2 in the 
ABC cells (Figure 6E and 6F). However, ectopic Bcl-2 
expression was not sufficient for complete rescue of ABC 
cells following the suppression of JMJD3, and maturation 
of procaspase-3 was still observed (Figure 6G and 6H). 
Thus, though Bcl-2 may also contribute to ABC cell 
survival, it is principally dependent upon NFkB signaling 
downstream of IRF4. 
Therapeutic delivery of JMJD3 siRNA inhibits 
DLBCL tumor growth and induces tumor cell 
death in a mouse model of disease
Although JMJD3 played a key role in tumor survival 
for both types in vitro (As summarized in Figure 7A), it 
remained unclear whether this was recapitulated in vivo. 
We then evaluated the effect of silencing-down of JMJD3 
on tumor progression in the mice with established DLBCL 
tumors. Mice were treated 4 times with intratumoral 
injections at 48 h intervals with either scrambled control 
siRNA, or JMJD3 siRNA at a final dose of 10 nmol 
per mouse (Figure 7B). Relative to the mice treated 
with scrambled controls, the JMJD3 siRNA treated 
group exhibited an arrested tumor growth (Figure 7C). 
Importantly, the expression of JMJD3, IRF4 and BCL2 
in tumor tissues derived from JMJD3 siRNA-treated mice 
were dramatically decreased when compared to tumors 
from the control animals (Figure 7D–7F). TUNEL analysis 
revealed an increase in percentage of apoptotic cells in 
JMJD3-depleted tumors (Figure 7G and 7H), concordant 
with the increased maturation of procaspase-3 in the 
JMJD3 siRNA treated group (Figure 7I).
DISCUSSION
Our current understanding of DLBCL delineates two 
major disease subgroups (ABC& GCB) that most likely 
reflect tumor derivation from B cells at discrete stages of 
differentiation. These two subtypes are associated with 
distinct genetic lesions, raising the notion that distinct 
mechanisms may regulate their survival [21–23, 27, 35]. 
Thus, while it was perhaps somewhat surprising to find 
that JMJD3 was critical to the survival of both subtypes, 
the precise mechanisms downstream of JMJD3 expression 
are somewhat different. 
A hallmark of ABC DLBCLs is the constitutive 
activation of the nuclear factor-κB (NF-κB) pathway, 
which plays a pivotal role in the survival of ABC DLBCL. 
Therefore, it was not unexpected that NF-κB played an 
obligatory role in tumor survival. In this case, JMJD3 
maintains cell survival principally by increasing IRF4 
expression and amplifying NF-κB signaling, though 
some effect might be attributed to increased levels of 
Bcl-2. By contrast, among GCB cells, the chromosomal 
translocations that are observed (almost exclusively) are 
those involving the BCL2 and MYC oncogenes. In fact, 
30–40% of GCB DLBCL cases harbor t (14;18) (q32;q21), 
which results in deregulated expression of Bcl- 2 [24, 36]. 
Since the MYC pathway promotes apoptosis via the 
intrinsic BCL2-dependent pathway [37], it is reasonable 
that the regulation of this survival pathway is both 
necessary and sufficient for the GCB tumor survival. 
Therefore, the suppression of BCL2 expression by JMJD3 
potentiates its amplification. It is interesting to speculate 
that in the minority of cases of GCB in which JMJD3 
is not found to be elevated, there may be alternative 
mechanisms to enhance and/or sustain BCL2 promoter 
activity. 
The epigenetic amplification of IRF4 by JMJD3 
is not likely to be unique to DLBCL. We observed 
elevated levels of the JMJD3 protein in other types of 
hematopoietic neoplasia, including both T and B cells 
lesions, suggesting that it may be a general mechanism 
to promote survival in the hematopoietic compartment, 
and supporting the idea that JMJD3 amplification is 
likely to be clinically important. Although JMJD3-IRF4 
axis seems no direct effect on GCB, we cannot rule out 
the possibility that these cells may be more sensitive to 
apoptosis when directly challenged with a therapeutic 
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Figure 4: The JMJD3-IRF4 axis mediates the anti-apoptotic effect via NF-κB signal pathway in ABC DLBCL. 
(A) Measurement of apoptosis using annexin-V/PI staining and flow cytometry of DLBCL cells following suppression of IRF4 via IRF4 
siRNA, scrambled siRNA was used as control. (B) Immunoblot analysis showing the depletion of IRF4 protein in IRF4 siRNA group as 
compared with the scrambled control siRNA group, as well as the effect of IRF4 depletion on caspase3 maturation. (C) Measurement of 
apoptosis using annexin-V/PI staining and flow cytometry of DLBCL cells that overexpression IRF4 following the depletion of JMJD3. 
(D) Immunoblot analysis evaluating the depletion of JMJD3 protein and overexpression of IRF4 protein in DLBCL cells and the combined 
effects of JMJD3 depletion and IRF4 overexpression on the expression of cleaved caspase3 and pro-caspase3 in DLBCL cells. (E) The 
effect of co-culture with an NFkB pathway inhibitor (PDTC) on ABC and GBC cell viability. (F) Immunoblot assay showing the combined 
effects of JMJD3 depletion and IRF4 overexpression on p-I-κB and I-κB expression in the cytoplasm of DLBCL cells and on p50 and p65 
expression in the nucleus of DLBCL cells relative to b-actin and lamin A, respectively. (G) Alterations in mRNA expression as evaluated 
by qPCR following ectopic expression of IRF4 in OCI-Ly3 cells. (H) Expression of IRF-4 and JMJD3 following ectopically overexpression 
of IRF-4 with or without PDTC. (I) Model for positive feedback along the JMJD3-IRF4-NFkB axis. The apoptosis and mRNA inductions 
shown are the mean ± S.E.M. of three independent experiments (*P < 0.01, **P < 0.001, Student’s t-test).
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agent or other pro-apoptotic insults. Saito et al. reported 
that relative low level of IRF4 in the GCB subtype blocked 
the downregulation of BCL6 expression, which is required 
by the post-germinal center B cell development [38]. Up 
till now, there is few data about the role of IRF4 in the 
GCB subtype of DLBCL. It has been reported that IRF4 
inhibits cell cycle progression of GCB-derived Burkitt’s 
lymphoma cells and induces terminal differentiation 
toward plasma cells through mechanisms independent of 
BCL6 downregulation [39]. In addition, the activation and 
polarization of macrophages in response to bacterial or 
helminth infection show that the JMJD3-IRF4 axis plays 
a pivotal role in regulating M2 macrophage polarization 
[11], suggesting that it may be a general mechanism of 
resistance to cell death that can be triggered in times of 
cellular stress. 
Clinically, the expression of JMJD3 is likely to be 
relevant to DLBCL malignancy since it is expressed in 92% 
of patient samples examined. Down-regulation of JMJD3 
results in amelioration of DLBCL in mouse models of disease, 
consistently. Although the intratumoral injection of siRNA 
we preformed does not seem likely to translate rapidly to the 
clinic, there may nonetheless be other mechanisms by which 
the JMJD3 axis could be targeted, including inhibitors of NF-
κB, or methyl transferase inhibition in tandem with cytotoxic 
chemotherapeutics. Altogether, our study helps further delineate 
the key players in the pathogenesis of DLBCL and thus provide 
more desirable targets for the control of this disease.
 Figure 5: BCL-2 accounts for a significant survival component of JMJD3 in GCB DLBCL.  Bcl-2 mRNA as evaluated by 
qPCR (A) and Bcl2 protein (B) as resolved by immunoblotting using GCB DLBCL cells (OCI-Ly19 and VAL) following depletion of JMJD3 
using specific siRNA, scramble siRNA used as control. (C) Schematic diagram of BCL-2 promoter regions (upper panel). ChIP-PCR analysis 
of H3K27me3 mark of the BCL2 promoter in OCI-Ly19 cells with depleted JMJD3 or control. (D) Densitometric quantification of the ChIP-
PCR analysis results. (E) Measurement of apoptosis using annexin-V/PI staining and flow cytometry of OCI-Ly19 and VAL cells depleted of 
JMJD3 combined with expression of Bcl-2 or control. (F) Immunoblot assay showing the depletion of JMJD3 proteins and overexpression 
of Bcl-2 proteins in DLBCL cells and the combined effects of JMJD3 depletion and Bcl-2 overexpression on caspase3 maturation in GCB 
DLBCL cells. The data shown are the mean ± S.E.M. of three independent experiments (*P < 0.05, **P < 0.01, Student’s t-test).
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Figure 6: Bcl-2 has limited impact in ABC DLBCL. The RNA (A) (qPCR) and protein (B) (immunoblot) expression levels of 
BCL-2 in OCI-Ly3 and SU-DHL-2 cells, two ABC DLBCL cell lines with depleted JMJD3 using specific siRNA or control siRNA. 
(C) Schematic diagram of BCL2 promoter regions (upper panel). ChIP-PCR analysis of H3K27me3 mark of the BCL2 promoter in OCI-
Ly3 cells depleted JMJD3 or not. Mouse IgG used as negative control, input used as loading control (lower panel). (D) Quantification of 
the ChIP-PCR analysis results. Relative mRNA (E) and protein expression levels (F) of IRF4 and Bcl-2 in DLBCL cells overexpressing 
IRF4 or not, and in absence or presence of PDTC. (G) Measurement of cell death using annexin-V/PI staining and flow cytometry of 
ABC DLBCL cells OCI-Ly3 and SU-DHL-2 that overexpress Bcl-2 following the depletion of JMJD3. (H) Immunoblot assay showing 
the depletion of JMJD3 and overexpression of BCL2 in DLBCL cells, as well as the combined effects of JMJD3 depletion and Bcl-2 
overexpression on cleaved caspase3 and pro-caspase3 expression in ABC DLBCL cells. The data shown are the mean ± S.E.M. of three 
independent experiments (*P < 0.05, **P < 0.01, Student’s t-test).
Oncotarget29395www.impactjournals.com/oncotarget
Figure 7: Therapeutic treatment with JMJD3 siRNA inhibits tumor growth and induces tumor apoptosis in DLBCL 
mouse model. (A) Model of distinct mechanisms of JMJD3 action in DLBCL. (B) Mouse model and schedule of long-term treatments. 
The DLBCL tumor model was developed by subcutaneous injection of 1 × 107 OCI-Ly3 (ABC DLBC) or OCI-Ly19 (GCB DLBC) cells into 
NOD/SCID mice on day 0. On day 31, 34, 37 and 40, the animals received injection of control siRNA or JMJD3 siRNA into tumors. All the 
tumors were isolated on day 41 for further analysis. (C) The tumor volume of OCI-Ly3 (left) and OCI-Ly19 (right) DLBCL tumor mouse 
models treated with JMJD3 siRNA or control siRNA. The RNA (D) (qPCR) and protein (E) (immunoblot) expression levels of JMJD3, IRF4 
and BCL-2 in OCI-Ly3 and OCI-Ly19 established tumors treated with JMJD3 siRNA or control siRNA. (F) Immunohistochemical staining 
showing the expression and distribution of JMJD3 and IRF4 in OCI-Ly3 and OCI-Ly19 established tumors depleted or not of JMJD3. Scale 
bar, 50 μm. Representative pictures (G) and the quantification of the percentage of apoptotic tumor cells of TUNEL staining (H) in OCI-Ly3 
and OCI-Ly19 established tumor sections. Scale bar, 50 μm. (I) Western blot assay showing the effect of JMJD3 depletion on pro-caspase3 
and cleaved caspase3 in OCI-Ly3 and OCI-Ly19 DLBCL tumors (β-actin used as loading control). (*P < 0.05, Student’s t-test).
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MATERIALS AND METHODS
Animals and cell lines
Male NOD/SCID mice aged 6–8 weeks were 
purchased from the Laboratory Animal Center, the 
Academy of Military Medical Sciences, (Peking, 
China). All animal experiments were performed 
according to Health guidelines of Nankai University 
Institutional Animal Use and Care Committee. The 
normal B cell line HMy2.CIR was purchased from 
the institutes for biological sciences of Chinese 
academy of sciences (Shanghai, China). DLBCL 
lines SU-DHL-2 and SU-DHL-8 were purchased 
from American Type Culture Collection (Manassas, 
VA). Five DLBCL cell lines (OCI-Ly3, OCI-Ly19, 
SU-DHL-4, SU-DHL-6 and VAL) were the kind gift 
of Dr. Jun Cheng (Tianjin Medical University Cancer 
Institute and Hospital, Tianjin, China). Pyrrolidine 
dithiocarbamate (PDTC) was purchased from Sigma-
Aldrich (#P8765, St Louis, MO). 
RNA isolation, RT-PCR and real-time PCR
Total RNA was extracted from DLBCL cells and 
tumor tissues from the mouse model using the TRIZOL 
reagent (Invitrogen). The experiment was performed 
according to the manufacturer’s protocol. Real-time 
PCRs were performed using TransStart Top Green qPCR 
SuperMix in a CFXTM Real-Time Thermal cycler (Bio- Rad) 
for sequence detection. The primers used in RT-PCR and 
real-time PCR are listed in Supplementary Table S1.  
Total, cytosolic, and nuclear protein extraction
Cell lysates from human DLBCL cells or tumor 
tissue cells were prepared with RIPA buffer in the presence 
of protease inhibitor cocktails. For nuclear and cytosolic 
extracts, the extraction was performed according to the 
manufacturer’s protocol of KeyGEN Nuclear-cytosol 
Extraction kit (KeyGEN Biotech, Nanjing, China) (Cat# 
KGP1100).
Vector construction
The human IRF4 and BCL2 expression plasmids 
were generated by inserting IRF4 fragment between 
Bam H I and Xba I and BCL2 between Xba I and 
Nhe I sites of the multiple cloning site (MCS) of pLV-
EF1α -MCS-IRES-Bsd vector (Biosettia, San Diego, 
CA). siRNA sequences for silencing human JMJD3 
(5′-GCUACACCUUGAGCACAAATdT-3′) and IRF4 
(5′-ACCUCGCA CUCUCAGUUUCdTdT-3′, 5′-UCCG 
AGAAGGCAUCGACAAdTdT-3′) genes were designed 
and chemically synthesized by RiboBio Company 
(Guangzhou, China). A scrambled sequence designed 
(RiboBio Co.) was used as control for knockdown 
analysis. The human JMJD3 expression vector pCMV-
JMJD3-HA was purchased (Addgene, Cambridge MA).
Protein and siRNA expression
Human DLBCL cells were transfected with pCMV-
JMJD3-HA, pLV-EF1α-IRF4-IRES-Bsd, pLV-EF1α-BCL2-
IRES-Bsd expression plasmids alone or co-transfected 
with siRNA of JMJD3. 106 DLBCL cells were plated in the 
12- well plate with medium without penicillin-streptomycin, 
then transfected with LipofectamineTM Transfection 
Reagent (Invitrogen) as per manufacturer’s instructions. 
Protein levels were determined by immunoblot. The effect 
of JMJD3 overexpression or suppression was investigated 
in cells either harvested for immunoblotting, RT-PCR 
and real-time PCR, or used for proliferation, apoptosis 
and CHIP assays after 48 hours of transfection.
Immunoblot and immunohistochemical analysis
Detection of protein expression by immunoblot was 
carried out according to the established protocols described 
previously [40]. JMJD3 (Cell Signal, Danvers, MA) (Cat# 
3457), IRF4 (Abcam, Cambridge, MA) (Cat# ab5184- 1), 
caspase-3 (Cell Signal) (Cat# 9665), Bcl-2 (Cell 
Signaling), (Cat# 2870), NF-κB (P65 subunit) (Abcam) 
(Cat# ab32536), NF-κB (P105/50 subunit) (Abcam) (Cat# 
ab32360), laminA (Cat# ab8980), (Abcam), IκBα (1:1000, 
Cat# ab32518, Abcam), p-IκBα (1:1000, Cat# ab133462, 
Abcam) and β-actin (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA) (Cat# sc-47778) antibodies were used. 
Secondary horseradish peroxidase - conjugated goat 
anti-rabbit or mouse antibodies (Bio-Rad) were detected 
by the enhanced chemiluminescence reagent (Millipore, 
Billerica, MA). Paraffin sections were incubated at 4°C 
overnight with the primary antibody after dewaxing 
and hydration. Anti-JMJD3 (Abcam) (Cat# ab38113) or 
-IRF4 (Abcam) were used at 1:50 dilution. Slides were 
incubated with a biotinylated secondary antibody for 
1.5 h, then developed with avidin-peroxidase and DAB 
and counterstained with hematoxylin. Dehydrated slides 
were mounted with neutral resin.
Analysis of apoptosis and proliferation
For annexin-V/PI analysis, cells were stained according 
to the manufacturer’s instructions (BD Biosciences, San Jose, 
CA) and cells positive for annexin-V detection were measured 
using FlowJo software (BD Biosciences). Proliferation 
assays were performed as per manufacturer’s protocol 
(Cell Proliferation Assay, Cell Counting Kit-8 (CCK- 8, 
Dojindo Laboratories, Shanghai, China) after seeding 2000 
cells in 96- well plates in complete medium 24 h following 
transfection with control vector, pCMV-JMJD3-HA vector or 
JMJD3 or scrambled siRNA.
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Chromatin immunoprecipitation (ChIP)
OCI-Ly3 cells in T75 flask were cross-linked by 1% 
formaldehyde. Glycine was used to quench the unreacted 
formaldehyde. The cells were harvested and sonicated 
following the instruction of EZ-ChIP™ kit (Millipore) 
(Cat# 17–371). Sample was centrifuged and supernatant 
was collected and first precleared with Protein G Agarose, 
then 10 μl supernatant was saved as input control. 1 μg 
anti-RNA Polymerase, 1 μg Normal Mouse IgG or 5 μg 
Mouse anti-Histone H3 (trimethyl K27) antibody (Abcam) 
(Cat# ab6002), was added to each supernatant fraction 
in tube used as the positive control, negative control, or 
H3K27me3 sample respectively and rotated overnight at 
4°C. The DNA purified from both input control samples 
and immunoprecipitations were subjected to PCR 
amplification for a 300 bp fragment of the IRF4 promoter. 
All PCR signals from immunoprecipitated DNA were 
normalized to PCR signals from non-immunoprecipitated 
input DNA. The primers used in PCR are listed in 
Supplementary Table S2.
Therapeutic treatment
Mice were separated randomly into two 
groups (n = 10 for each group). 1 × 107 OCI-Ly3 (ABC 
subtype) or OCI-Ly19 (GCB subtype) cells were 
xenografted into each mouse through subcutaneous 
injections. 32 days later, mice received 4 times of tumor 
multipoint injections, at 3-day intervals, of control siRNA 
or JMJD3 siRNA (10 nmol per mouse). Mice were 
sacrificed 24 hours after the final treatment and body 
weights and tumor volumes were determined. The tumor 
tissues subjected to further analysis. TUNEL (Promega, 
Madison, Wisconsin) immunohistochemical staining was 
performed according to the manufacturer’s protocol.
Statistical analysis
All data are presented as mean ± S.E.M. Statistical 
analysis of the data was performed using the GraphPad 
Prism software (GraphPad Soft ware, Inc. La Jolla, CA). 
Differences between individual groups were analyzed 
by paired t-test or χ2, as appropriate. P value < 0.05 was 
considered statistically significant.
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